Stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease
Author:
Open Access
- 16 November 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 33 (12) , 2320-2325
Abstract
Nuclear localization of signal transducer and activator of transcription (Stat) 5 marks good prognosis in estrogen receptor/progesterone receptor-positive breast tumors. This positive characteristic is counteracted by studies in laboratory animals demonstrating that deregulated Stat5 activity may convert proper mammary development into a latent oncogenic process. Tumorigenesis is initiated during the parity cycles, most probably during pregnancy, when the activated Stat5 antagonizes or manipulates parity’s protective mechanisms. For example, it can alter the differentiation/proliferation balance, induce growth hormone signaling, cause specific alteration in chromatin structure, inhibit tumor-suppressor activity and induce DNA damage that counteracts the enhanced DNA-damage response exerted by parity. Palpable tumors develop after a latent period from individual cells. This happens in the estropausal period in transgenic mice maintaining deregulated Stat5 activity in the mammary gland, or during involution, months after transplantation of transfected cells with constitutively active Stat5. Candidate vulnerable cells are those which maintain high nuclear Stat5 activity. Due to the hazardous outcome of deregulated Stat5 activity in these cells, such as induced DNA damage or high cyclin D1 activity, the gland is prone to transformation. The developing tumors are mostly adenocarcinomas or their subtypes. They are estrogen receptor–positive and maintain a specific Stat5 gene signature that allows tracking their inducer. From a clinical point of view, deregulated Stat5 activity represents a genuine risk factor for breast cancer. Monitoring Stat5 activity during vulnerable periods and developing specific tools for its suppression in breast epithelial cells could potentially limit new incidence of the disease.Keywords
This publication has 82 references indexed in Scilit:
- Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in miceBlood, 2012
- Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and functionAmerican Journal of Physiology-Cell Physiology, 2012
- Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genesNucleic Acids Research, 2012
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell, 2012
- Differential oestrogen receptor binding is associated with clinical outcome in breast cancerNature, 2012
- Parity-Induced Decrease in Systemic Growth Hormone Alters Mammary Gland Signaling: A Potential Role in Pregnancy Protection from Breast CancerCancer Prevention Research, 2010
- Role of ER in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesisCarcinogenesis, 2010
- Prolactin Inhibits BCL6 Expression in Breast Cancer through a Stat5a-Dependent MechanismCancer Research, 2010
- Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5AGenes & Development, 2009
- Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5BGenes & Development, 2008